Citadel Advisors’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $96.7M | Buy |
3,135,057
+1,805,122
| +136% | +$44.6M | 0.01% | 994 |
|
|
2026
Q1 | $28.7M | Buy |
1,329,935
+1,225,234
| +1,170% | +$26.5M | ﹤0.01% | 1909 |
|
|
2025
Q4 | $2.5M | Sell |
104,701
-190,353
| -65% | -$3.88M | ﹤0.01% | 5511 |
|
|
2025
Q3 | $4.01M | Sell |
295,054
-316,141
| -52% | -$3.29M | ﹤0.01% | 4759 |
|
|
2025
Q2 | $4.98M | Buy |
611,195
+234,097
| +62% | +$2M | ﹤0.01% | 4127 |
|
|
2025
Q1 | $2.96M | Buy |
377,098
+16,504
| +5% | +$191K | ﹤0.01% | 4789 |
|
|
2024
Q4 | $5.37M | Buy |
360,594
+42,723
| +13% | +$698K | ﹤0.01% | 3844 |
|
|
2024
Q3 | $4.86M | Sell |
317,871
-149,292
| -32% | -$2.35M | ﹤0.01% | 3989 |
|
|
2024
Q2 | $7.11M | Buy |
467,163
+112,242
| +32% | +$1.81M | ﹤0.01% | 3246 |
|
|
2024
Q1 | $6.7M | Buy |
354,921
+78,997
| +29% | +$1.37M | ﹤0.01% | 3516 |
|
|
2023
Q4 | $5.27M | Sell |
275,924
-9,923
| -3% | -$159K | ﹤0.01% | 3704 |
|
|
2023
Q3 | $5.13M | Sell |
285,847
-449,782
| -61% | -$9.04M | ﹤0.01% | 3606 |
|
|
2023
Q2 | $14.9M | Sell |
735,629
-1,030,379
| -58% | -$19.6M | ﹤0.01% | 2180 |
|
|
2023
Q1 | $32.2M | Buy |
1,766,008
+1,122,779
| +175% | +$21.5M | 0.01% | 1469 |
|
|
2022
Q4 | $13.3M | Buy |
643,229
+616,739
| +2,328% | +$17M | ﹤0.01% | 2442 |
|
|
2022
Q3 | $693K | Sell |
26,490
-25,393
| -49% | -$672K | ﹤0.01% | 7764 |
|
|
2022
Q2 | $1.31M | Buy |
51,883
+31,975
| +161% | +$783K | ﹤0.01% | 6412 |
|
|
2022
Q1 | $628K | Sell |
19,908
-141,902
| -88% | -$4.75M | ﹤0.01% | 8834 |
|
|
2021
Q4 | $6.55M | Buy |
161,810
+133,722
| +476% | +$5.19M | ﹤0.01% | 3827 |
|
|
2021
Q3 | $979K | Sell |
28,088
-14,061
| -33% | -$438K | ﹤0.01% | 8212 |
|
|
2021
Q2 | $1.16M | Sell |
42,149
-11,003
| -21% | -$314K | ﹤0.01% | 7976 |
|
|
2021
Q1 | $1.49M | Sell |
53,152
-42,361
| -44% | -$1.47M | ﹤0.01% | 7113 |
|
|
2020
Q4 | $2.48M | Sell |
95,513
-20,471
| -18% | -$495K | ﹤0.01% | 4910 |
|
|
2020
Q3 | $1.99M | Sell |
115,984
-254,042
| -69% | -$5.68M | ﹤0.01% | 4727 |
|
|
2020
Q2 | $9.15M | Buy |
370,026
+338,436
| +1,071% | +$9.13M | ﹤0.01% | 2331 |
|
|
2020
Q1 | $439K | Sell |
31,590
-25,494
| -45% | -$317K | ﹤0.01% | 6684 |
|
|
2019
Q4 | $577K | Buy |
57,084
+2,042
| +4% | +$17.2K | ﹤0.01% | 6595 |
|
|
2019
Q3 | $501K | Sell |
55,042
-14,495
| -21% | -$116K | ﹤0.01% | 6748 |
|
|
2019
Q2 | $553K | Buy |
69,537
+52,018
| +297% | +$521K | ﹤0.01% | 6665 |
|
|
2019
Q1 | $219K | Buy |
+17,519
| New | +$190K | ﹤0.01% | 8084 |
|
Other funds holding RCUS
GS
SCM
WP
Citadel Advisors's RCUS Position: Q2 2026 in Review
Citadel Advisors increased its Arcus Biosciences (RCUS) stake by 136% in Q2 2026, buying an estimated $44.6M and bringing the position to 3,135,057 shares worth $96.7M. The position accounts for 0.01% of the portfolio, ranked #994.
Citadel Advisors first reported a position in RCUS in Q1 2019 and has held it in 30 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.
- Citadel Advisors held 3,135,057 shares of Arcus Biosciences worth $96.7M as of Q2 2026.
- Citadel Advisors bought 1,805,122 Arcus Biosciences shares in Q2 2026, an estimated $44.6M.
- Arcus Biosciences made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #994 holding.
- Citadel Advisors first reported a position in Arcus Biosciences in Q1 2019 and has held it in 30 quarters since.
- 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.